Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with juvenile dermatomyositis: a real-world multicentre study.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Grein, Ingrid Herta RotsteinPinto, Natalia Balera Ferreira
Groot, Noortje
Martins, Camila Bertini
Lobo, Aline
Aikawa, Nadia Emi
Barbosa, Cassia
Terreri, Maria Teresa
da Fraga, Aline Coelho Moreira
de Oliveira, Sheila Knupp Feitosa
Sztajnbok, Flavio
Paim Marques, Luciana B
Islabão, Aline Garcia
Appenzeller, Simone
Bica, Blanca
de Oliveira Sato, Juliana
Magalhães, Claudia Saad
Ferriani, Virgínia
Pasmans, Hella
Schepp, Rutger
van der Klis, Fiona
de Roock, Sytze
Wulffraat, Nico
Pileggi, Gecilmara Salviato
Type
ArticleLanguage
en
Metadata
Show full item recordTitle
Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with juvenile dermatomyositis: a real-world multicentre study.Published in
Pediatr Rheumatol Online J 2020; 18(1):87PMID
33176806ae974a485f413a2113503eed53cd6c53
10.1186/s12969-020-00479-w
Scopus Count
Collections
Related articles
- Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with childhood systemic lupus erythematosus: a real-world interventional multi-centre study.
- Authors: Rotstein Grein IH, Pinto NF, Lobo A, Groot N, Sztajnbok F, da Silva CAA, Paim Marques LB, Appenzeller S, Islabão AG, Magalhães CS, de Almeida RG, Bica B, Fraga M, da Fraga ACM, Dos Santos MC, Robazzi T, Terreri MTR, Bandeira M, Pasmans H, Schepp R, van der Klis F, de Roock S, Wulffraat N, Pileggi G
- Issue date: 2020 Jul
- Immunogenicity of quadrivalent HPV and combined hepatitis A and B vaccine when co-administered or administered one month apart to 9-10 year-old girls according to 0-6 month schedule.
- Authors: Gilca V, Sauvageau C, Boulianne N, De Serres G, Couillard M, Krajden M, Ouakki M, Murphy D, Trevisan A, Dionne M
- Issue date: 2014
- Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study.
- Authors: Sankaranarayanan R, Prabhu PR, Pawlita M, Gheit T, Bhatla N, Muwonge R, Nene BM, Esmy PO, Joshi S, Poli UR, Jivarajani P, Verma Y, Zomawia E, Siddiqi M, Shastri SS, Jayant K, Malvi SG, Lucas E, Michel A, Butt J, Vijayamma JM, Sankaran S, Kannan TP, Varghese R, Divate U, Thomas S, Joshi G, Willhauck-Fleckenstein M, Waterboer T, Müller M, Sehr P, Hingmire S, Kriplani A, Mishra G, Pimple S, Jadhav R, Sauvaget C, Tommasino M, Pillai MR, Indian HPV Vaccine Study Group.
- Issue date: 2016 Jan
- Efficacy, safety, and immunogenicity of a quadrivalent HPV vaccine in Japanese men: A randomized, Phase 3, placebo-controlled study.
- Authors: Mikamo H, Yamagishi Y, Murata S, Yokokawa R, Han SR, Wakana A, Sawata M, Tanaka Y
- Issue date: 2019 Mar 14
- Safety and immunogenicity of the quadrivalent human papillomavirus (qHPV) vaccine in HIV-positive Spanish men who have sex with men (MSM).
- Authors: Hidalgo-Tenorio C, Ramírez-Taboada J, Gil-Anguita C, Esquivias J, Omar-Mohamed-Balgahata M, SamPedro A, Lopez-Ruz M, Pasquau J
- Issue date: 2017 Jul 18